FDA Approves Libtayo (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Read more
Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries Read more
Lilly’s bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19 Read more
Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics Read more
Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program Read more
Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients Read more